Delving into the Latest Updates on Ad5-SSTR/TK-RGD(The University of Alabama at Birmingham) with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms-

Target

SSTR x TK

Action

modulators

Mechanism

SSTR modulators(Somatostatin receptor modulators), thymidine kinase modulators(Thymidine kinase modulators)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication-

Inactive Indication

Recurrent ovarian cancer

Originator Organization

The University of Alabama at Birmingham

Active Organization-

Inactive Organization

The University of Alabama at Birmingham

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

A Phase I Study of AD5.SSTR/TK.RGD; A Tropism Modified Adenovirus Vector for Intraperitoneal Delivery of Therapeutic Genes and Additional Capability of Noninvasive Imaging of Gene Transfer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (Infectivity Enhanced Adenoviral Vectors for Ovarian CA)

In spite of surgical and chemotherapeutic advances, long term survival for advanced and recurrent gynecologic cancers remains dismal and no curative treatment for recurrent disease exists. Novel treatment strategies are needed. This is a study to determine the maximally tolerated dose of and toxicities associated with intraperitoneal delivery of an infectivity enhanced adenovirus that expresses a suicide gene and an gene that allows imaging of gene transfer. This vector will be given in combination with intravenous ganciclovir in patients with recurrent ovarian and other gynecological cancers.

Start Date01 Aug 2009

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

100 Clinical Results associated with Ad5-SSTR/TK-RGD(The University of Alabama at Birmingham)

Login to view more data

100 Translational Medicine associated with Ad5-SSTR/TK-RGD(The University of Alabama at Birmingham)

Login to view more data

100 Patents (Medical) associated with Ad5-SSTR/TK-RGD(The University of Alabama at Birmingham)

Login to view more data

1

Literatures (Medical) associated with Ad5-SSTR/TK-RGD(The University of Alabama at Birmingham)

01 Jul 2010·IDrugs : the investigational drugs journal

American Society of Gene & Cell Therapy--13th Annual Meeting.

Author: Romano, Gaetano

The American Society of Gene & Cell Therapy's 13th Annual Meeting, held in Washington, DC, included topics covering new developments in the field of gene therapy. This conference report highlights selected presentations on adenoviral therapies for the treatment of cancer, HIV immunotherapies and gene/cell therapies for the treatment of genetic disorders. Investigational drugs discussed include the TAG vaccine and INGN-007 (both Gradalis Inc), AdCD40L (Uppsala University), Ad5-SSTR/TK-RGD (University of Alabama at Birmingham), CGTG-102 (Oncos Therapeutics Ltd) and lexgenleucel-T (VIRxSYS Corp).

100 Deals associated with Ad5-SSTR/TK-RGD(The University of Alabama at Birmingham)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent ovarian cancer	Phase 1	United States	The University of Alabama at Birmingham	01 Aug 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASGCT2010	Phase 1	Recurrent Carcinoma	-	Ad5.SSTR/TK.RGD	rudkigqoxw(wolwyjhjwq) = ugwyqkoxjd ilnnocrtas (lahxwxjcxv ) View more	Positive	01 May 2010
				Ganciclovir (GCV)	knfzudwucx(fuowymgmzl) = gttjdjqysk xbfldwtjgv (qyalpansyl )